News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Teladoc trades near $5.11 with ~$909M market cap and $166.9M free cash flow, making a tactical long candidate.
  • Eli Lilly's Foundayo approval boosts its obesity franchise, while pricing pressure and execution risks threaten near-term margins.
  • Analyst recommends long entry at $940.06, stop at $880, and target $1,150 on Eli Lilly.
  • President Trump said U.S. forces are clearing the Strait of Hormuz and that Iranian minelaying vessels have been sunk.
  • U.S. and Iranian representatives began talks in Islamabad hosted by Pakistan under a fragile ceasefire.
  • Strait developments could increase volatility in shipping and oil markets.

Latest Articles

Jefferies Raises ArcelorMittal to Buy, Cites Stronger EU Steel Outlook

Jefferies Raises ArcelorMittal to Buy, Cites Stronger EU Steel Outlook

Jefferies upgraded ArcelorMittal (MT) from Hold to Buy and increased its price target to EUR62.00 from EUR44.00, pointing to a structurally stronger outlook for European steel driven by policy changes. The firm projects substantially higher 2027 EBITDA and expects EU production rates and prices to rise as import flows decline under new tariff rules…

Cantor Fitzgerald Cuts Lyft Price Target to $14 After Mixed Q4 Results

Cantor Fitzgerald Cuts Lyft Price Target to $14 After Mixed Q4 Results

Cantor Fitzgerald trimmed its 12-month price target on Lyft to $14.00 from $21.00 while retaining a Neutral rating after the ride-hailing company's fourth-quarter report. Bookings broadly matched Street expectations and EBITDA beat by roughly 5%, but rides growth slowed and first-quarter EBITDA guidance landed below consensus at the mid-point.

Ault Capital Rolls Out Public Testnet for Finance-Focused Ault Blockchain

Ault Capital Rolls Out Public Testnet for Finance-Focused Ault Blockchain

Ault Capital Group has launched the public testnet for Ault Blockchain, a Cosmos SDK Layer 1 with full Ethereum Virtual Machine compatibility built for trading, settlement, and institutional onchain workloads. The testnet provides a live environment for developers, validators, and infrastructure operators to assess core functionality. Governance wi…

Hochschild: A Tactical Long for Gold and Silver Bulls

Hochschild: A Tactical Long for Gold and Silver Bulls

Hochschild Mining (HCHDF) looks like a workable long for metal bulls. Price is above key short-term moving averages, RSI is constructive, and short interest has collapsed since late 2025. Given the OTC listing and limited public metrics, this is a trading idea focused on momentum and position sizing rather than a full fundamental re-rate.

Oppenheimer Raises Monro Muffler to Outperform, Sets $40 Price Target

Oppenheimer Raises Monro Muffler to Outperform, Sets $40 Price Target

Oppenheimer upgraded Monro Muffler Brake Inc. (NASDAQ: MNRO) from Perform to Outperform and assigned a $40.00 price target. The firm cited stabilizing company dynamics under new senior leadership and expects strengthening sales and operating leverage as sector conditions improve. Recent company results showed an EPS beat for Q3 FY2026 but a slight …

Goldman Sachs Starts Coverage on Samsara With Buy Rating and $36 Target

Goldman Sachs Starts Coverage on Samsara With Buy Rating and $36 Target

Goldman Sachs has initiated coverage of Samsara Inc (NYSE:IOT) with a Buy rating and a $36 price target, implying roughly 32% upside from the stock's current price of $27.20. The bank frames Samsara as a highly defensible software growth asset that combines edge hardware and cloud software to digitize physical operations. Other broker activity and …

Truist Increases Gilead Sciences Price Target to $152 Following Strong Q4; Highlights HIV Franchise and Upcoming Catalysts

Truist Increases Gilead Sciences Price Target to $152 Following Strong Q4; Highlights HIV Franchise and Upcoming Catalysts

Truist Securities raised its price target on Gilead Sciences to $152 from $145 and kept a Buy rating after the company reported Q4 2025 results that outperformed consensus on revenue and adjusted EPS. The upgrade reflects confidence in Gilead’s HIV franchise and a pipeline of upcoming catalysts, though some investor debate over Yeztugo’s $800 milli…

DA Davidson Lifts Hasbro Price Target to $110 After Strong Q4 2025 Results

DA Davidson Lifts Hasbro Price Target to $110 After Strong Q4 2025 Results

DA Davidson raised its price objective on Hasbro to $110 from $80 following the company's stronger-than-expected fourth-quarter 2025 results. The firm left its rating at Neutral while citing a broad-based beat across segments, robust margins and a conservative 2026 outlook. Morgan Stanley also increased its target and maintained an Overweight stanc…